Real-World test for advanced lung cancer treatment combo
NCT ID NCT06376084
Summary
This study is observing how well a combination of the drug Osimertinib and standard chemotherapy works for people with a specific type of advanced lung cancer (EGFR-positive NSCLC) in a real-world setting. It involves 532 adult patients who have already started this specific treatment plan with their doctor. The main goal is to see how long patients live without their cancer getting worse and to monitor the safety of this treatment combination outside of a controlled clinical trial.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEOPLASMS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Shanghai, China
Conditions
Explore the condition pages connected to this study.